In breast cancer, the inhibition of SPP1 and CSF1 could prevent the assembly of an immunosuppressive tumor microenvironment and partially or completely sensitize otherwise refractory quasi-mesenchymal tumors to anti-CTL4 immune checkpoint blockade therapy [13]. This evidence concerns the gene SPP1 and mesenchymal cell neoplasm.